How Technology Is Transforming Multiple Sclerosis Care
Technology is opening new possibilities for how multiple sclerosis is monitored, treated and managed. In this episode of the ECTRIMS Podcast, host Brett Drummond speaks with Prof. Ellen Mowry of John...
12 Elo 31min
Should High-Risk Populations Be Screened for Multiple Sclerosis?
Could multiple sclerosis one day be detected before symptoms appear? And if so, should we be actively screening people who are at higher risk? In this episode of the ECTRIMS–MS Journal collaboration ...
30 Heinä 32min
How Geography, Healthcare Systems and Access Shape the Multiple Sclerosis Journey
Where someone lives can profoundly influence their multiple sclerosis journey. While advances in diagnosis and treatment have transformed MS care in many parts of the world, millions of people still f...
16 Heinä 27min
MS Research Briefs: MRI Biomarkers, Machine Learning and the Future of MS Diagnosis
Welcome to MS Research Briefs, a new ECTRIMS podcast series delivering an expert guided tour of important new studies in multiple sclerosis research. In each episode, leading MS experts will take a sm...
2 Heinä 23min
Vitamin D and Multiple Sclerosis: Separating Evidence from Expectation
Vitamin D and multiple sclerosis have been linked for decades, but how strong is the evidence – and what does it mean for clinical practice? In this episode of the ECTRIMS Podcast, host Brett Drummond...
18 Kesä 31min
Can the revised 2024 McDonald Diagnostic criteria solve the misdiagnosis problem in multiple sclerosis?
In this episode of the ECTRIMS Podcast, recorded in collaboration with the Multiple Sclerosis Journal "Controversies in MS" series, host Prof. Anneke van der Walt moderates a discussion between Prof. ...
3 Kesä 33min
Fenebrutinib in Relapsing MS: FENhance Trial Results Explained
New Phase 3 data presented at the AAN conference 2026 provide compelling evidence that fenebrutinib may represent a high-efficacy oral treatment option for people living with relapsing multiple sclero...
22 Huhti 26min
